Literature DB >> 2054311

Methodology of antiemetic trials: a review.

M Tonato1, F Roila, A Del Favero.   

Abstract

Chemotherapy-related nausea and vomiting can be controlled with available antiemetics in a high percentage of patients, while emesis remains a critical problem in some subgroups and with certain drugs. In the ceaseless attempt to find newer drugs and better treatment modalities, a sound methodology in antiemetic research is essential. Several factors should always be considered when planning an antiemetic trial: first, the different emetic power of various chemotherapy agents, their dosages and route and schedule of administration and second, the type of antiemetic used, its dosage and timing, and its possible combination with other antiemetics. Important factors which influence outcome but which are often under-evaluated are those related to patient population such as age, gender, and previous experience with chemotherapy. Considering the relevance of subjective phenomena in nausea and vomiting, it is essential that any study be randomized and double blinded. The parallel type of study design is preferable to the cross-over and a large number of patients is usually required to achieve meaningful results. Efficacy and toxicity should be properly evaluated by trained personnel in a standardized way, using a validated, relatively simple methodology.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2054311     DOI: 10.1093/oxfordjournals.annonc.a057871

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  31 in total

1.  Effects of altering the time of administration and the time frame of quality of life assessments in clinical trials: an example using the EORTC QLQ-C30 in a large anti-emetic trial.

Authors:  J Pater; D Osoba; B Zee; W Lofters; M Gore; E Dempsey; M Palmer; C Chin
Journal:  Qual Life Res       Date:  1998-04       Impact factor: 4.147

2.  Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study.

Authors:  D Tsuji; M Yokoi; K Suzuki; T Daimon; M Nakao; H Ayuhara; Y Kogure; K Shibata; T Hayashi; K Hirai; K Inoue; T Hama; K Takeda; M Nishio; K Itoh
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

3.  Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy.

Authors:  Mari Yokoi; Daiki Tsuji; Kenichi Suzuki; Yohei Kawasaki; Masahiko Nakao; Hideaki Ayuhara; Yuuki Kogure; Kazuhiko Shibata; Toshinobu Hayashi; Keita Hirai; Kazuyuki Inoue; Toshihiro Hama; Koji Takeda; Makoto Nishio; Kunihiko Itoh
Journal:  Support Care Cancer       Date:  2017-11-24       Impact factor: 3.603

4.  Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.

Authors:  Chi-Ting Liau; Nei-Min Chu; Hsueh-Erh Liu; Robert Deuson; Jade Lien; Jen-Shi Chen
Journal:  Support Care Cancer       Date:  2005-03-16       Impact factor: 3.603

Review 5.  Methodological issues in antiemetic studies.

Authors:  M Aapro
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850

Review 6.  Are there differences among the serotonin antagonists?

Authors:  M Tonato; F Roila; A Del Favero
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

7.  Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.

Authors: 
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 8.  Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

9.  Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.

Authors:  Hiroyoshi Takemoto; Junichi Nishimura; Takamichi Komori; Ho Min Kim; Hirofumi Ota; Rei Suzuki; Masakazu Ikenaga; Masataka Ikeda; Hirofumi Yamamoto; Taroh Satoh; Taishi Hata; Ichiro Takemasa; Tsunekazu Mizushima; Yuichirou Doki; Masaki Mori
Journal:  Int J Clin Oncol       Date:  2016-07-27       Impact factor: 3.402

Review 10.  Methodology of trials with antiemetics.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1996-07       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.